China-based InventisBio (Shanghai) Co., Ltd (SHA: 688382) has announced the successful completion of a Phase II study for its oral TYK2 inhibitor, D-2570, in the treatment of psoriasis, with positive outcomes.
Understanding Psoriasis and the Role of TYK2 Inhibition
Psoriasis is an immune-mediated chronic disease characterized by recurrent, inflammatory, and systemic symptoms, often induced by a combination of genetic and environmental factors. The condition presents significant challenges for patients, and effective treatments are crucial for managing the disease and improving quality of life.
D-2570’s Efficacy in Phase II Study
Preliminary results from the Phase II study indicate that D-2570 met the primary endpoint at all three tested doses. Additionally, other key efficacy measures, including PASI 90 and PASI 100 responses—defined as a patient achieving 90% and 100% improvement from baseline in the Psoriasis Area and Severity Index (PASI) score—showed significant improvement. The static physician global assessment (sPGA) 0/1, which indicates complete or near-complete clearance of skin lesions, also demonstrated substantial progress.-Fineline Info & Tech
Leave a Reply